Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mineralocorticoid Receptor Signaling in Vascular Dysfunction After Preeclampsia
NCT07345845Phase 1Withdrawn
- Start
- Dec 2025
- Primary completion
- Feb 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1 trial of eplerenone in preeclampsia. Primary endpoint: Change in microvascular endothelial function at 1 hour. Planned start Dec 2025; status: withdrawn.
02
Drugs
eplerenone
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT07345845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345845.